Holen Sie sich die Stockscreener-App
5.39
3.26%
0.17
Handel nachbörslich:
5.39
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Immuneering reports 17.3-month survival in pancreatic cancer trial - Investing.com
Immuneering stock jumps on pancreatic cancer trial data By Investing.com - Investing.com Nigeria
Immuneering stock jumps on pancreatic cancer trial data - Investing.com
Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 - Quiver Quantitative
Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival - Stock Titan
Immuneering Corp stock (US45255L1089): clinical updates keep biotech investors watching - AD HOC NEWS
Immuneering stock (US45255L1089): Insider buying puts the biotech back in focus - AD HOC NEWS
Immuneering Corp Q1 2026 10-Q Report: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Immuneering Corporation Reports Q1 2026 Financial Results and Announces Positive Phase 2a Pancreatic Cancer Trial Data - Minichart
Immuneering Hikes on Q1 Figures - Baystreet.ca
Immuneering to present pancreatic cancer trial data at ASCO - Investing.com
Immuneering Corp 1Q 2026: Revenue ($13.78M), Net income ($13.46M), EPS ($0.21) — 10-Q Summary - TradingView
Immuneering (IMRX) advances atebimetinib into MAPKeeper 301 Phase 3 - Stock Titan
Immuneering reports Q1 2026 net loss $13.5M, $198.6M cash runway into 2029 - TradingView
Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX) - Stock Titan
Pancreatic cancer patient gets 27 months progression-free on Immuneering drug - Stock Titan
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corp stock (US45255L1089): Q4 beat and 174% YTD surge - AD HOC NEWS
TradingKey - TradingKey
The one question every Immuneering Corporation (IMRX) investor should ask (Smart Money Flows) 2026-05-11Crowd Risk Alerts - newser.com
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors - TipRanks
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely - Yahoo Finance
Insider Buyers At Immuneering Sitting On US$361k Profit - Sahm
Immuneering Corp (IMRX) Stock Price, Quote, News & History - Benzinga
Immuneering brings 55-patient pancreatic survival update to ASCO oral - Stock Titan
Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification - Stock Titan
Immuneering (IMRX) Reveals Promising Genetic Data at Upcoming AA - GuruFocus
Immuneering presents genetic data on atebimetinib resistance - Investing.com
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond - The Manila Times
In 123 patients, Immuneering's cancer drug showed rare resistance signals - Stock Titan
Immuneering Corporation (IMRX) Stock: Technical Strength Check (Risk Aversion) 2026-04-18Hot Stocks - Newser
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears - Yahoo Finance
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Needham healthcare fireside chat adds Immuneering CEO on April 13 - Stock Titan
Immuneering CorporationClass A Common Stock (NQ: IMRX - The Chronicle-Journal
Immuneering Corp Stock: Precision Oncology Innovator with Deep Pipeline Potential for North American - AD HOC NEWS
Bull Bear: Can Immuneering Corporation scale operations efficiently2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Immuneering Corp Stock (ISIN: US45255L1089) Faces Short-Term Pressure Amid Clinical Momentum and Ana - AD HOC NEWS
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - The Manila Times
Immuneering Corp (IMRX) CPO acquires shares through employee stock plan - Stock Titan
New MEK approach in 64 cancer patients shows fewer resistance mutations - Stock Titan
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - AOL.com
Immuneering (IMRX) to Release Earnings on Thursday - MarketBeat
Piper Sandler cuts Immuneering stock price target on launch timing - Investing.com
Why Immuneering Corporation stock could outperform in 2026Earnings Growth Report & Community Supported Trade Ideas - Naître et grandir
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen - MarketBeat
Immuneering Corporation Q4 & Full Year 2025 Earnings: EPS Beats -$0.18 Estimate - Bayelsa Watch
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Immuneering 2025 10-K: $0 Revenue, $(1.27) EPS and $(56.0)M Net Loss - TradingView
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Immuneering Corporation Reports 64% Overall Survival in Phase 2a Trial for First-Line Pancreatic Cancer and Outlines 2026 Development Plans - Quiver Quantitative
Immuneering to Present at the Leerink Global Healthcare Conference - The Manila Times
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):